https://www.frontiersin.org/journals/stroke RSS Feed for Frontiers in Stroke | New and Recent Articles en-us Frontiers Feed Generator,version:1 2026-09-13T04:00:16.354+00:00 60 https://www.frontiersin.org/articles/10.3389/fstro.2026.1903852 https://www.frontiersin.org/articles/10.3389/fstro.2026.1903852 2026-09-03T00:00:00Z Original Research Chung-Huan SunIan ChunKazuma NakagawaStacy BrownSamuel TsappidiFerdinand HuiYi ZhangRony SalemGuangxiang ZhangDaniel GalanisMatthew Koenig https://www.frontiersin.org/articles/10.3389/fstro.2026.1918465 https://www.frontiersin.org/articles/10.3389/fstro.2026.1918465 2026-08-25T00:00:00Z Perspective Håkon Ihle-HansenHege Ihle-HansenRolf A. BlauenfeldtJesse DawsonSøren Z. DiederichsenGuri Hagberg https://www.frontiersin.org/articles/10.3389/fstro.2026.1913292 https://www.frontiersin.org/articles/10.3389/fstro.2026.1913292 2026-08-24T00:00:00Z Original Research Ronald BwambaleRonald SsenyongaMark KaddumukasaMartha SajatovicAggrey David Mukose https://www.frontiersin.org/articles/10.3389/fstro.2026.1879025 https://www.frontiersin.org/articles/10.3389/fstro.2026.1879025 2026-08-21T00:00:00Z Original Research Ayush AgarwalChristine TunklAlexandra KraussEmily R. RamageMirjam R. HeldnerStefan T. GernerTeresa UllbergLeonardo A. CarboneraJatinder S. MinhasAristeidis KatsanosMatias J. AletAbdul H. K. Y. KhanFaddi Saleh ValezTamer RoushdyLinxin LiBogdan CiopleiasZhe Kang LawRadhika LotlikarSusanna M. ZuurbierMaria G. MosconiShirsho ShreyanShakti ShresthaGisele S. SilvaAnnemarei Ranta https://www.frontiersin.org/articles/10.3389/fstro.2026.1845862 https://www.frontiersin.org/articles/10.3389/fstro.2026.1845862 2026-08-21T00:00:00Z Original Research Haroon KhanYang WangJing ChenXiao-Bing XieWei XuMeng LiDong-Ling HuangJiannan XiaoChuan-Cheng Ren https://www.frontiersin.org/articles/10.3389/fstro.2026.1915602 https://www.frontiersin.org/articles/10.3389/fstro.2026.1915602 2026-08-14T00:00:00Z Systematic Review Ahmed AljabaliDeema AlhayaliHallie Taylor-WedgeTodd A. LaffayeMajd Al-AhmedAyham HarahshehMohammed AlamoushKhaled DweikMayowa A. OsundijiAmir A. MbondeCumara B. O'CarrollBart M. DemaerschalkEhab Harahsheh 2 territories) were observed in 65%. Conventional vascular risk factors were infrequent (0%−21%), whereas deep vein thrombosis (43%) and systemic embolism (41%) frequently preceded or coincided with stroke onset. Malignancy (70%) and autoimmune disease (25%) were the main NBTE etiologies. Anticoagulation was initiated in 70%, and 21% underwent valvular surgery. Over a median follow-up of 2.0 months, stroke recurred in 43% and death occurred in 49% of patients. Malignant etiology (aOR 10.3, P < 0.001) and metastases (aOR 3.9, P < 0.001) were associated with increased mortality, while VKA use (aOR 0.08, P < 0.001) and autoimmune etiology (aOR 0.1, P < 0.001) were associated with lower mortality. Malignancy (aOR 2.8, P < 0.001) and DOAC use (aOR 5.2, P = 0.012) were associated with increased risk of recurrent stroke.ConclusionNBTE should be considered in stroke patients lacking conventional vascular risk factors, particularly those with malignancy or autoimmune disease. Malignancy and DOAC use were associated with higher recurrent stroke risk, while VKA use was associated with lower mortality; however, these anticoagulant-class findings should be considered hypothesis-generating and interpreted cautiously given the case-report evidence base, small treatment subgroups, potential confounding, and limited follow-up.What this study addsBy synthesizing patient-level data from published case reports and case series, this review provides a stroke-focused characterization of NBTE, including clinical presentation, infarct topography, underlying etiologies, management strategies, recurrent cerebrovascular events, and mortality. The findings highlight multifocal infarction, malignancy-associated NBTE, and recurrent stroke despite anticoagulation as key clinical concerns, while emphasizing that observed associations with anticoagulant class should be viewed as hypothesis-generating rather than definitive treatment guidance]]> https://www.frontiersin.org/articles/10.3389/fstro.2026.1840317 https://www.frontiersin.org/articles/10.3389/fstro.2026.1840317 2026-08-14T00:00:00Z Original Research Jin Un KimZhen CahilogZehra KadaniTeledalase OlajoyegbeDarren FernandesDhiraj AilKarishma OojageerTelma Da SilvaSaeedur RahmanPeter Kabunga https://www.frontiersin.org/articles/10.3389/fstro.2026.1847419 https://www.frontiersin.org/articles/10.3389/fstro.2026.1847419 2026-08-14T00:00:00Z Original Research Eva Birgitte AamodtKarim BoreiThomas PotterFarhaan Vahidy https://www.frontiersin.org/articles/10.3389/fstro.2026.1800285 https://www.frontiersin.org/articles/10.3389/fstro.2026.1800285 2026-08-07T00:00:00Z Original Research Yingxia LiRuixing ZhangYang LuoYouquan Gu 2.86 indicated a higher risk of poor short-term functional status.ConclusionsAdmission levels of DBIL and DBLR are significantly correlated with the degree of neurological impairment and short-term (7 ± 2 days) in-hospital functional status in AIS patients, where higher values indicate more severe acute neurological deficits and poorer early outcomes. Elevated DBLR is independently associated with poor short-term functional status, and the exploratory cutoff of DBLR > 2.86 (OR = 5.169, 95% CI: 1.623–16.461, P = 0.005) may assist in early risk stratification. However, their independent predictive ability is limited (all AUCs < 0.7). Therefore, these biomarkers should only be used as auxiliary tools in combination with clinical scores such as the NIHSS, and their clinical value should not be overinterpreted.]]> https://www.frontiersin.org/articles/10.3389/fstro.2026.1861562 https://www.frontiersin.org/articles/10.3389/fstro.2026.1861562 2026-07-31T00:00:00Z Review Jin YangTing WangYaoyue HuCuiying LiuTianliang ShiHeng Zhao https://www.frontiersin.org/articles/10.3389/fstro.2026.1904901 https://www.frontiersin.org/articles/10.3389/fstro.2026.1904901 2026-07-29T00:00:00Z Original Research Molly M. JacobsCharles Ellis https://www.frontiersin.org/articles/10.3389/fstro.2026.1859301 https://www.frontiersin.org/articles/10.3389/fstro.2026.1859301 2026-07-28T00:00:00Z Original Research Chen Ee LowHon Jen WongChun En YauJia Yang TanYao Neng TeoYao Hao TeoJasper R. SenffReinier TackAndrew F. W. HoBernard P. L. ChanLeonard L. L. YeoJoshua Y. P. YeoChing-Hui SiaBenjamin Y. Q. Tan 18years old at first AIS onset, and received treatment at a local hospital between 2005 and 2020. Patients were stratified according to sex-specific hemoglobin concentration cut-offs on anemia severity and polycythemia from the World Health Organization. Multivariate logistic regression and Cox proportional hazards modeling were performed, adjusting for demographics and cardiovascular risk factors.ResultsA total of 56,884 ischemic stroke patients were included, of which 66.8% had no anemia, 15.7% had mild anemia, 12.2% had severe anemia, and 5.3% had polycythemia. The cohort was predominantly male (57%), with a median age of 68 years. The median follow-up duration was 10-years (IQR 7–13). Compared to patients with normal-range hemoglobin, both mild and severe anemia was associated with elevated short-term and long-term risks of all-cause mortality. Severe anemia was associated with the highest risk of all-cause mortality, with hazard ratios of 1.99 (95%CI:1.92–2.06) at 30-days, 1.73 (95%CI:1.66–1.81) at 1-year, and 1.52 (95%CI:1.41–1.64) at 5-years. However, the excess risk associated with severe anemia appeared to attenuate at 10-years, whilst the elevated risk persisted among patients with mild anemia.ConclusionIn this nationwide stroke registry, anemia is prevalent among AIS patients and is significantly associated with both short-term and long-term mortality.]]> https://www.frontiersin.org/articles/10.3389/fstro.2026.1807741 https://www.frontiersin.org/articles/10.3389/fstro.2026.1807741 2026-07-24T00:00:00Z Original Research Elizabeth TobenerMolly JacobsCharles Ellis https://www.frontiersin.org/articles/10.3389/fstro.2026.1887056 https://www.frontiersin.org/articles/10.3389/fstro.2026.1887056 2026-07-23T00:00:00Z Original Research Kivian Obed Matamoros PadillaRoberto Daniel Padilla ValerianoEleonora Espinoza-TurcioHenry Noel Castro-RamosLysien Ivania ZambranoSelvin Z. Reyes-Garcia https://www.frontiersin.org/articles/10.3389/fstro.2026.1769395 https://www.frontiersin.org/articles/10.3389/fstro.2026.1769395 2026-07-20T00:00:00Z Review Tshibambe N. TshimbombuArsene Daniel NyalundjaGates Mulume IragiJosué Aganze MwambaliSamira Braimah ShardowMelissa Ewurakua AmoakoKyle E. ThurmannDaniel I. GonzalezPaige BanyasJudea WigginsSupreet Kaur https://www.frontiersin.org/articles/10.3389/fstro.2026.1838151 https://www.frontiersin.org/articles/10.3389/fstro.2026.1838151 2026-07-14T00:00:00Z Original Research Robert TrueickJonathan ShpigelmanOmar DabashJohn McCalligMuhammad Ahmad AshfaqueMuneeb QuidwaiLisa DonaghyPatricia GuilfoyleLavanya SaivaJames O'NeillMichael J. Daly https://www.frontiersin.org/articles/10.3389/fstro.2026.1847066 https://www.frontiersin.org/articles/10.3389/fstro.2026.1847066 2026-07-08T00:00:00Z Brief Research Report Ning LiErin L. AbnerSilvia KotonLena MathewsKunihiro MatsushitaAnna M. Kucharska-Newton https://www.frontiersin.org/articles/10.3389/fstro.2026.1807730 https://www.frontiersin.org/articles/10.3389/fstro.2026.1807730 2026-07-07T00:00:00Z Original Research Michael H. ParrishLeonardo BonilhaKarly PikelCaitlin ScottStefanie WoodHaley N. VerKuilenSouvik Sen https://www.frontiersin.org/articles/10.3389/fstro.2026.1917786 https://www.frontiersin.org/articles/10.3389/fstro.2026.1917786 2026-07-06T00:00:00Z Correction Oladotun V. OlalusiJoseph YariaAkintomiwa MakanjuolaRufus AkinyemiMayowa OwolabiAdesola Ogunniyi https://www.frontiersin.org/articles/10.3389/fstro.2026.1759945 https://www.frontiersin.org/articles/10.3389/fstro.2026.1759945 2026-07-01T00:00:00Z Original Research Elisabeth Ronne EngströmChristoffer NybergMia von Euler 24 h from start of symptoms compared to 4.5% in national data. Three percent were treated with thrombectomy and 11.1% with thrombolysis. The numbers were small but those with the lowest percentage of arrival < 3 h, and of reperfusion treatment, all had the longest distances to the first hospital. 26.1 and 17.9% in two municipalities had an unknown time window from start of symptoms. A majority of the population would have shorter distances to thrombectomy centers outside Sweden.ConclusionOur data shows a higher incidence of ischemic stroke in the study area in the rural northern Sweden. Persons with stroke in this area are unlikely to receive acute care in accordance with the Swedish national stroke guidelines.]]>